The primary endpoint was the mean change in HbA1c, from baseline to week 52. Secondary endpoints regarding glycemic control included the proportion of patients who reached an HbA1c target of less than 7% by week 52, and the mean change in FPG from baseline to week 52. Secondary endpoints in the assessment of cardiovascular risk factors included the change in systolic and diastolic BP and change in body weight from the beginning of the study to week 52.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
 Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.